206 related articles for article (PubMed ID: 14693546)
1. In vitro inhibition of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid.
Ducasse-Cabanot S; Cohen-Gonsaud M; Marrakchi H; Nguyen M; Zerbib D; Bernadou J; Daffé M; Labesse G; Quémard A
Antimicrob Agents Chemother; 2004 Jan; 48(1):242-9. PubMed ID: 14693546
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis.
Cohen-Gonsaud M; Ducasse S; Hoh F; Zerbib D; Labesse G; Quemard A
J Mol Biol; 2002 Jul; 320(2):249-61. PubMed ID: 12079383
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis.
Veyron-Churlet R; Zanella-Cléon I; Cohen-Gonsaud M; Molle V; Kremer L
J Biol Chem; 2010 Apr; 285(17):12714-25. PubMed ID: 20178986
[TBL] [Abstract][Full Text] [Related]
4. The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance.
Banerjee A; Sugantino M; Sacchettini JC; Jacobs WR
Microbiology (Reading); 1998 Oct; 144 ( Pt 10)():2697-2704. PubMed ID: 9802011
[TBL] [Abstract][Full Text] [Related]
5. Structural rearrangements occurring upon cofactor binding in the Mycobacterium smegmatis β-ketoacyl-acyl carrier protein reductase MabA.
Küssau T; Flipo M; Van Wyk N; Viljoen A; Olieric V; Kremer L; Blaise M
Acta Crystallogr D Struct Biol; 2018 May; 74(Pt 5):383-393. PubMed ID: 29717709
[TBL] [Abstract][Full Text] [Related]
6. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II.
Marrakchi H; Ducasse S; Labesse G; Montrozier H; Margeat E; Emorine L; Charpentier X; Daffé M; Quémard AK
Microbiology (Reading); 2002 Apr; 148(Pt 4):951-960. PubMed ID: 11932442
[TBL] [Abstract][Full Text] [Related]
7. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
[TBL] [Abstract][Full Text] [Related]
8. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
9. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II.
Marrakchi H; Lanéelle G; Quémard AK
Microbiology (Reading); 2000 Feb; 146 ( Pt 2)():289-296. PubMed ID: 10708367
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.
Mdluli K; Slayden RA; Zhu Y; Ramaswamy S; Pan X; Mead D; Crane DD; Musser JM; Barry CE
Science; 1998 Jun; 280(5369):1607-10. PubMed ID: 9616124
[TBL] [Abstract][Full Text] [Related]
11. Role of Serine140 in the mode of action of Mycobacterium tuberculosis β-ketoacyl-ACP Reductase (MabA).
Rosado LA; Caceres RA; de Azevedo WF; Basso LA; Santos DS
BMC Res Notes; 2012 Sep; 5():526. PubMed ID: 23006410
[TBL] [Abstract][Full Text] [Related]
12. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
[TBL] [Abstract][Full Text] [Related]
13. The Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III activity is inhibited by phosphorylation on a single threonine residue.
Veyron-Churlet R; Molle V; Taylor RC; Brown AK; Besra GS; Zanella-Cléon I; Fütterer K; Kremer L
J Biol Chem; 2009 Mar; 284(10):6414-24. PubMed ID: 19074144
[TBL] [Abstract][Full Text] [Related]
14. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
Rawat R; Whitty A; Tonge PJ
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
[TBL] [Abstract][Full Text] [Related]
15. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
16. Mycobacterium tuberculosis beta-ketoacyl-ACP reductase: alpha-secondary kinetic isotope effects and kinetic and equilibrium mechanisms of substrate binding.
Silva RG; Rosado LA; Santos DS; Basso LA
Arch Biochem Biophys; 2008 Mar; 471(1):1-10. PubMed ID: 18155153
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
Argyrou A; Vetting MW; Aladegbami B; Blanchard JS
Nat Struct Mol Biol; 2006 May; 13(5):408-13. PubMed ID: 16648861
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.
Slayden RA; Lee RE; Barry CE
Mol Microbiol; 2000 Nov; 38(3):514-25. PubMed ID: 11069675
[TBL] [Abstract][Full Text] [Related]
19. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
[TBL] [Abstract][Full Text] [Related]
20. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
